Predict your next investment

HEALTHCARE | Biotechnology
agensys.com

See what CB Insights has to offer

Founded Year

1997

Stage

Acquired | Acquired

Total Raised

$103.4M

Valuation

$0000 

About Agensys

Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less severe side effects. All of Agensys' cancer targets must meet the following criteria: (1) a novel molecule and/or a novel utility in cancer; (2) expression in a significant percentage of patients' specimens; (3) limited expression in normal vital tissues; and (4) structural and functional features suitable for therapeutic intervention. The Company is generating fully human antibodies to multiple targets from its portfolio, including those directed to prostate, kidney, bladder, colon, lung, ovary and pancreatic cancers. The Company's portfolio also contains multiple validated targets for small molecule and vaccine products that it intends to develop through partnerships with pharmaceutical and biotechnology companies.

Agensys Headquarter Location

1545 17th Street

Santa Monica, California, 90404,

United States

310-820-8029

Latest Agensys News

Patients with cancer at high risk for death due to breakthrough COVID-19 infections

Jan 3, 2022

Disclosures: Choueiri reports honoraria from, consultant/advisory roles with, travel accommodations and expenses from and/or research funding to his institution from Agensys, Alexion Pharmaceuticals, Alligent, ASCO, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly & Co., EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Janssen Oncology, Merck, Michael J. Hennessy Associates, Sanofi/Aventis, Seagen/Astellas, Takeda and several other entities outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Fully vaccinated patients with cancer who developed breakthrough COVID-19 infections appeared at high risk for hospitalization and death, according to study results published in Annals of Oncology. Researchers also reported that patients with hematologic malignancies continued to be overrepresented among the fully vaccinated cancer population with breakthrough infections. Data derived from Schmidt AL, et al. Ann Oncol. 2021;doi:10.1016/j.annonc.2021.12.006. “Patients with cancer who develop breakthrough COVID-19 infections have substantial comorbidities and can suffer from severe outcomes, including ICU admission and death,” Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology and Kidney Cancer at Dana-Farber Cancer Institute and Jerome Nancy Kohlberg chair and professor of medicine at Harvard Medical School, told Healio. Methodology Toni K. Choueiri Choueiri and colleagues used data from the COVID-19 and Cancer Consortium to evaluate clinical characteristics and outcomes of 54 fully vaccinated patients with cancer (median age, 65.5 years; 65% women; 70% white; 35% with hematologic malignancies) who experienced breakthrough COVID-19 infection. They considered patients fully vaccinated after receiving two doses of either of the mRNA vaccines (BNT162b2, Pfizer/BioNTech; mRNA-1273, Moderna), the NIAD vaccine or one dose of the Johnson & Johnson vaccine. The investigators also identified 1,656 unvaccinated patients and 77 partially vaccinated patients eligible for study inclusion. “One emerging question has been how patients with cancer fare after COVID-19 breakthrough infection, which could have significant implications for this specific vulnerable patient population,” Choueiri said. All-cause mortality at 30 days among fully vaccinated patients compared with the unvaccinated cohort served as the primary endpoint. Key findings Results showed 65% of fully vaccinated patients with breakthrough COVID-19 infection required hospitalization, 19% required ICU admission or mechanical ventilation, and 13% died within 30 days. Researchers observed similar rates in the unvaccinated cohort. All-cause mortality at 30 days did not differ significantly between the fully vaccinated and unvaccinated cohorts (adjusted OR = 1.08; 95% CI, 0.41-2.82). The researchers did not use booster vaccinations as part of the vaccinated cohort, as the data on booster doses emerged after the current data collection. “COVID-19 severity was comparable between vaccinated patients who developed breakthrough infections and unvaccinated patients with cancer even after controlling for potential confounding factors,” Choueiri said. “Of note, this is retrospective study and not randomized, so confounding factors are always possible.” A significant proportion of fully vaccinated patients with hematologic malignancies had breakthrough COVID-19 infections. Implications These findings provide evidence of the importance of not underestimating COVID-19 severity among vaccinated patients with cancer, Choueiri said. “There is a great need for strict precautions, including social distancing, mask wearing and related health measures such as vaccination of close contacts and booster shot administration, among this vulnerable population,” he added. “The COVID-19 and Cancer Consortium is continuing to collect information on vaccinated patients, especially with booster vaccinations. We will also expand our research to collect more detailed oncology therapies to see if certain therapies given to patients may impact the efficacy of the vaccine.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Agensys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Agensys is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Agensys Patents

Agensys has filed 157 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Monoclonal antibodies
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/2/2018

1/19/2021

Experimental cancer drugs, Monoclonal antibodies, Oncology, Monoclonal antibodies for tumors, Surgical removal procedures

Grant

Application Date

4/2/2018

Grant Date

1/19/2021

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Oncology, Monoclonal antibodies for tumors, Surgical removal procedures

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.